Chemists deduce the correct structure of the A and B baulamycins

July 27, 2017 by Bob Yirka, report
Previously proposed and actual molecular structures of the baulamycins. Credit: Nature (2017). doi:10.1038/nature23265

(—A team of chemists at the University of Bristol has correctly deduced the correct structure of the A and B baulamycins. In their paper published in the journal Nature, the team describes how they discovered that the baulamycins had been incorrectly structured and how they developed the new method for deducing the structure of flexible compounds in general. Severin Thompson and Thomas Hoye with the University of Minnesota offer a News & Views piece on the work done by the group in the same issue and explain how the new method could be used to help medical scientists identify natural compounds that might offer medical benefits.

Despite their seemingly simple nature, molecules do not always display their true structure—they actually show a number of unique conformations. This makes it difficult for chemists attempting to understand or recreate them. Especially difficult is getting a handle on the true structure of flexible compounds. In this new effort, the researchers describe their discovery that the structure of A and B baulamycins had been incorrectly described by previous researchers and their efforts to find its correct structure, which led them to develop a new procedure to deduce the structure of a wide variety of .

A and B baulamycins are polyketide antibiotics with long, flexible carbon chains. Because of their benefits, researchers have tried to create synthetic versions of them, but until now, have failed. The reason appears to be earlier incorrect descriptions of their structure. After making that discovery, the researchers set about determining the true structure.

The new developed by the team involves using both computational methods and nuclear magnetic resonance spectra of the original material to figure out which configurations the compounds naturally take. They then made mixtures of possible isomers of baulamycin A with unequal ratios to identify which of the matched the compound in its natural state. Once they had the correct structure, the team synthesized the compound, which can be used as an antibiotic. The team suggests the same process could be used by other researchers to deduce the correct of other natural complex molecules.

Explore further: Chemists discover structure of cancer drug candidate

More information: Synergy of synthesis, computation and NMR reveals correct baulamycin structures, Nature (2017).

Small-molecule, biologically active natural products continue to be our most rewarding source of, and inspiration for, new medicines. Sometimes we happen upon such molecules in minute quantities in unique, difficult-to-reach, and often fleeting environments, perhaps never to be discovered again. In these cases, determining the structure of a molecule—including assigning its relative and absolute configurations—is paramount, enabling one to understand its biological activity. Molecules that comprise stereochemically complex acyclic and conformationally flexible carbon chains make such a task extremely challenging . The baulamycins (A and B) serve as a contemporary example. Isolated in small quantities and shown to have promising antimicrobial activity, the structure of the conformationally flexible molecules was determined largely through J-based configurational analysis, but has been found to be incorrect. Our subsequent campaign to identify the true structures of the baulamycins has revealed a powerful method for the rapid structural elucidation of such molecules. Specifically, the prediction of nuclear magnetic resonance (NMR) parameters through density functional theory—combined with an efficient sequence of boron-based synthetic transformations, which allowed an encoded (labelled) mixture of natural-product diastereomers to be prepared—enabled us rapidly to pinpoint and synthesize the correct structures.

Related Stories

Chemists discover structure of cancer drug candidate

May 19, 2014

Chemists at The Scripps Research Institute (TSRI) have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials in cancer patients.

Residual dipolar couplings unveil structure of small molecules

February 17, 2011

German chemists at the Technische Universitaet Muenchen and the Karlsruhe Institute of Technology introduced a new method for identifying chemical compounds. The approach they used is an improvement on nuclear magnetic resonance ...

Recommended for you

Greater than the sum of its parts

September 18, 2018

When it comes to designing and optimizing mechanical systems, scientists understand the physical laws surrounding them well enough to create computer models that can predict their properties and behavior. However, scientists ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.